Literature DB >> 17950909

PARP-1 activation in the ERK signaling pathway.

Malka Cohen-Armon1.   

Abstract

PARP-1 is a highly conserved DNA-binding protein, the most abundant member of the polyADP-ribose polymerases (PARP) family, which catalyzes post-translational modification of proteins by polyADP-ribosylation. This modification affects protein-protein and protein-DNA interactions. Binding of PARP-1 to breakages in damaged DNA causes its activation and auto-polyADP-ribosylation in a process that is pivotal for DNA repair. Our recent findings outlined an alternative mechanism of PARP-1 activation via a direct interaction with phosphorylated ERK2 (externally regulated kinase), which is unrelated to DNA damage and does not involve PARP-1 binding to DNA. Furthermore, ERK2-induced PARP-1 activation dramatically amplifies ERK-signals, enhancing ERK-induced phosphorylation of the transcription factor Elk1 and enhancing core histone acetylation and expression of the Elk1 target gene, c-fos. Thus, PARP-1 activation in the ERK signaling pathway mediates epigenetic mechanisms promoting growth, proliferation and differentiation regulated by the Raf-MEK-ERK phosphorylation cascade.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17950909     DOI: 10.1016/j.tips.2007.08.005

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  63 in total

1.  Further studies on the hypothesis of PARP-1 inhibition as a strategy for lessening the long-term effects produced by perinatal asphyxia: effects of nicotinamide and theophylline on PARP-1 activity in brain and peripheral tissue : nicotinamide and theophylline on PARP-1 activity.

Authors:  C Allende-Castro; P Espina-Marchant; D Bustamante; E Rojas-Mancilla; T Neira; M A Gutierrez-Hernandez; D Esmar; J L Valdes; P Morales; P J Gebicke-Haerter; M Herrera-Marschitz
Journal:  Neurotox Res       Date:  2012-02-04       Impact factor: 3.911

2.  cAMP-independent non-pigmentary actions of variant melanocortin 1 receptor: AKT-mediated activation of protective responses to oxidative DNA damage.

Authors:  María Castejón-Griñán; Cecilia Herraiz; Conchi Olivares; Celia Jiménez-Cervantes; Jose Carlos García-Borrón
Journal:  Oncogene       Date:  2018-04-06       Impact factor: 9.867

Review 3.  Role of PARP-1 in prostate cancer.

Authors:  Dhanraj Deshmukh; Yun Qiu
Journal:  Am J Clin Exp Urol       Date:  2015-04-25

4.  Androgen and PARP-1 regulation of TRPM2 channels after ischemic injury.

Authors:  Takeru Shimizu; Tara A Macey; Nidia Quillinan; Jelena Klawitter; Anne-Laure L Perraud; Richard J Traystman; Paco S Herson
Journal:  J Cereb Blood Flow Metab       Date:  2013-06-26       Impact factor: 6.200

5.  HMGN1 protein regulates poly(ADP-ribose) polymerase-1 (PARP-1) self-PARylation in mouse fibroblasts.

Authors:  Aya Masaoka; Natalie R Gassman; Padmini S Kedar; Rajendra Prasad; Esther W Hou; Julie K Horton; Michael Bustin; Samuel H Wilson
Journal:  J Biol Chem       Date:  2012-06-26       Impact factor: 5.157

6.  Proteomic dissection of cell type-specific H2AX-interacting protein complex associated with hepatocellular carcinoma.

Authors:  Xiaoli Yang; Peng Zou; Jun Yao; Dong Yun; Huimin Bao; Ruyun Du; Jing Long; Xian Chen
Journal:  J Proteome Res       Date:  2010-03-05       Impact factor: 4.466

Review 7.  Beyond DNA repair, the immunological role of PARP-1 and its siblings.

Authors:  Maria Manuela Rosado; Elisabetta Bennici; Flavia Novelli; Claudio Pioli
Journal:  Immunology       Date:  2013-08       Impact factor: 7.397

8.  Neuronal NOS and cyclooxygenase-2 contribute to DNA damage in a mouse model of Parkinson disease.

Authors:  Tuan Hoang; Dong-Kug Choi; Makiko Nagai; Du-Chu Wu; Tetsuya Nagata; Delphine Prou; Glenn L Wilson; Miquel Vila; Vernice Jackson-Lewis; Valina L Dawson; Ted M Dawson; Marie-Françoise Chesselet; Serge Przedborski
Journal:  Free Radic Biol Med       Date:  2009-07-17       Impact factor: 7.376

9.  A selective eradication of human nonhereditary breast cancer cells by phenanthridine-derived polyADP-ribose polymerase inhibitors.

Authors:  Dana Inbar-Rozensal; Asher Castiel; Leonid Visochek; David Castel; Françoise Dantzer; Shai Izraeli; Malka Cohen-Armon
Journal:  Breast Cancer Res       Date:  2009-11-09       Impact factor: 6.466

10.  Catastrophic NAD+ depletion in activated T lymphocytes through Nampt inhibition reduces demyelination and disability in EAE.

Authors:  Santina Bruzzone; Floriana Fruscione; Sara Morando; Tiziana Ferrando; Alessandro Poggi; Anna Garuti; Agustina D'Urso; Martina Selmo; Federica Benvenuto; Michele Cea; Gabriele Zoppoli; Eva Moran; Debora Soncini; Alberto Ballestrero; Bernard Sordat; Franco Patrone; Raul Mostoslavsky; Antonio Uccelli; Alessio Nencioni
Journal:  PLoS One       Date:  2009-11-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.